Literature DB >> 12701936

Pre-assessment to assess the match between cost-effectiveness results and decision makers' information needs: an illustration using two cases in rehabilitation medicine in The Netherlands.

Maarten J IJzerman1, Robert P B Reuzel, Hans L Severens.   

Abstract

OBJECTIVE: To determine if a pre-assessment can be used to establish whether cost-effectiveness results would meet the actual information needs of Dutch healthcare decision makers.
METHODS: Two recent studies in rehabilitation medicine served as study material. Based on Wholey, a limited pre-assessment was performed in which the potential impact of cost-effectiveness analysis (CEA) results on intended users' decision making was assessed. Desk research and semi-structured interviews with several intended users of CEA results were performed. These included general practitioners, representatives of health insurance companies, the Health Care Insurance Board (CvZ), and medical guidelines committees.
RESULTS: In day-to-day decision making of the interviewed decision makers, a cost-effectiveness criterion seemed to be of limited importance. Instead, results from clinical effectiveness studies and budget impact studies appeared to be sufficient. CvZ, however, preferred relative cost-effectiveness to be a criterion for inclusion in future reimbursement guidelines. In both cases the limited pre-assessments changed the expectations of the investigators regarding decision-making impact of an economic evaluation.
CONCLUSION: This study revealed that the use of CEA results for Dutch micro- and meso-level healthcare decision making is not self-evident. The main purpose of CEA results is to support health policy making and planning at a macroeconomic level. Pre-assessment can be a valuable tool in designing a CEA to support the actual information needs of the decision makers.

Mesh:

Year:  2003        PMID: 12701936     DOI: 10.1017/s0266462303000035

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  3 in total

Review 1.  Pharmacoeconomic studies in Italy: a critical review of the literature.

Authors:  D Cornago; L Li Bassi; P De Compadri; L Garattini
Journal:  Eur J Health Econ       Date:  2006-12-21

2.  Economic evidence at the local level : options for making it more useful.

Authors:  Kees van Gool; Gisselle Gallego; Marion Haas; Rosalie Viney; Jane Hall; Robyn Ward
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Stakeholder engagement in economic evaluation: Protocol for using the nominal group technique to elicit patient, healthcare provider, and health system stakeholder input in the development of an early economic evaluation model of chimeric antigen receptor T-cell therapy.

Authors:  Kednapa Thavorn; Justin Presseau; Mackenzie Wilson; Terry Hawrysh; Ian D Graham; Harold Atkins; Natasha Kekre; Doug Coyle; Manoj M Lalu; Dean A Fergusson; Kelvin Kw Chan; Daniel A Ollendorf
Journal:  BMJ Open       Date:  2021-08-12       Impact factor: 2.692

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.